On July 30, 2026, DFZQ bought 203,500 shares of KEYMED BIO-B at an average of HKD 72.8753 per share, involving about HKD 14.83 million.

Prior to the acquisition, DFZQ's long position in KEYMED BIO-B was 14.89 million shares, representing 4.98%; following the acquisition, the holding changed to 15.10 million shares, with the long position ratio rising to 5.05%.

Source: Hong Kong Exchanges and Clearing Limited.